1-3 of 3
Noa Lowenton-Spier
Close
Sort by
Journal Articles

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Yael C. Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Moshe Mittelman, Inna Tzoran, Vladimir Vainstein, Noa Lowenton-Spier, Natan Melamed, Ella Krayzler, Ilana Pereg, Irit Avivi Mazza
Journal: Blood
Blood (2023) 142 (Supplement 1): 2014.
https://doi.org/10.1182/blood-2023-185830
Published: 2023
Journal Articles

Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

Yael C Cohen, Moshe E Gatt, Efrat Luttwak, Noa Lavi, Chezi Ganzel, Evgeni Chubar, Ory Rouvio, Iuliana Vaxman, Oren Pasvolsky, Mouna Ballan, Tamar Tadmor, Anatoly Nemets, Osnat Jarchowsky, Olga Shvetz, Ofer Shpilberg, Najib Dally, Merav Leiba, Assaf Weiner, Mor Zada, Shuang-Yin Wang, Chamutal Gur, Noa Lowenton-Spier, Liron Goor-Porges, Ido Amit, Irit Avivi
Journal: Blood
Blood (2022) 140 (Supplement 1): 4426–4427.
https://doi.org/10.1182/blood-2022-164572
Published: 2022
Journal Articles

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

Yael C Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Noa Lowenton-Spier, Liron Gez-Aaronson, Natan Melamed, Irit Avivi
Journal: Blood
Blood (2022) 140 (Supplement 1): 10131–10132.
https://doi.org/10.1182/blood-2022-164722
Published: 2022